From JPMA On assuming the office of Chairman
Changes in the Environment Surrounding the Pharmaceutical Industry
The pharmaceutical industry is currently undergoing a variety of rapid changes in the environment surrounding us, and the structure of the market and industry, sources of competitiveness, and means of business activities are also changing dramatically. Until now, the mainstream business model was one of "vertical integration," in which a single company produced everything in the value chain from research and development to sales in-house.
In terms of competitiveness of pharmaceutical companies, it is important to keep in mind that a variety of factors are becoming the source of competitiveness, ranging from scientific and sales capabilities to highly independent corporate governance, human rights, diversity, and SDGs (Sustainable Development Goals) initiatives.
The pharmaceutical industry must now transform itself to meet the increasingly diverse and sophisticated healthcare needs on a global scale.
Japan Pharmaceutical Manufacturers Association
Yasushi Okada, Chairman
Toward the Establishment of a Foundation for the Pharmaceutical Industry
The spread of novel coronavirus infection has revealed the fragility of Japan's vaccine development infrastructure. It is essential to strengthen Japan's drug discovery capabilities not only to respond to possible future pandemics, but also to meet the unmet medical needs that still exist today by creating innovative new drugs to protect the lives and health of the Japanese people.
To this end, it is essential to create a life science cluster in Japan, where people with a strong entrepreneurial spirit gather, venture companies start up cutting-edge research, and various research institutions are concentrated; to develop a Japanese big data infrastructure to promote digital transformation (DX); and to evaluate innovations appropriately. It is important to build a pharmaceutical industry infrastructure, or healthcare ecosystem, in Japan that is centered on these three elements.
We will do our utmost to ensure that the public understands that the pharmaceutical industry is an indispensable and important industry for creating innovative innovations, extending the healthy life expectancy of the Japanese people, and contributing to Japan's economic growth, and that it will receive tremendous support. We will also actively engage in discussions with the many stakeholders in the industry and work toward the formation of an internationally competitive life science cluster in Japan, the development of a big data infrastructure, and the establishment of a NHI drug price system that appropriately evaluates innovation.
(From the May 20 press conference by the JPMA President)
Japan Pharmaceutical Manufacturers Association (JPMA)
Japan Pharmaceutical Manufacturers Association (JPMA)
JPMA was founded in 1968 as an organization of R&D-oriented pharmaceutical companies with the aim of contributing to the improvement of health and welfare of people around the world through research and development of ethical drugs for use in hospitals, clinics, and other medical institutions.
JPMA is dedicated to the realization of patient-participatory medicine through activities to deepen understanding of pharmaceuticals and policy recommendations for the sound development of the pharmaceutical industry.
As a member organization of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), JPMA is engaged in global activities in cooperation with other organizations to address issues related to medicine and pharmaceuticals around the world.
Aiming to contribute to society through the development of new drugs Japan Pharmaceutical Manufacturers Association